FDA Clears Teleflex’s ARROW NextStep Retrograde Femoral Length Dialysis Catheters

It’s been a busy week for Teleflex with the company’s announcement of its acquisition of microlaparoscopic device company Eon Surgical and last week’s CE mark for the Arrow® GPSCath® Balloon Dilatation Catheter. Now the device company tells us it has received FDA 510(k) clearance for its ARROW® NextStep® Retrograde Femoral Length Dialysis Catheters with their claimed ease of insertion and sustained high flow rate.

Background

The ARROW NextStep Retrograde Hemodialysis Catheter is the first of its kind designed to take better advantage of the blood flow dynamics within the heart through its unique reversed port configuration, where the venous port resides in the superior vena cava and the arterial port in the right atrium, resulting in reduced recirculation and high flow rates. The unique NextStep Tip is designed for smooth, over-the-wire transitions during catheter insertions and exchanges.

Company comments

“Providing clinicians with the ARROW NextStep Femoral Length Catheters continues a series of new product introductions that demonstrates our commitment to enhance patient outcomes and improve ease of use for clinicians,” said Linda Beneze, President and General Manager, Specialty Division. “We are proud to add the ARROW NextStep Retrograde Femoral Length Catheter to our portfolio.”

Source: Teleflex, Inc., Business Wire

 

- in: Categories